<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1699-714X</journal-id>
<journal-title><![CDATA[Revista de la OFIL ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. OFIL·ILAPHAR]]></abbrev-journal-title>
<issn>1699-714X</issn>
<publisher>
<publisher-name><![CDATA[Organización de Farmacéuticos Ibero-Latinoamericanos]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1699-714X2020000100010</article-id>
<article-id pub-id-type="doi">10.4321/s1699-714x20200001000010</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Imunoprofilaxia do vírus sincicial respiratório com palivizumabe em crianças em hospital da zona sul de São Paulo]]></article-title>
<article-title xml:lang="en"><![CDATA[Immunoprophylaxis of respiratory syncytial virus with palivizumab in children at a hospital in the southern zone of São Paulo]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lima]]></surname>
<given-names><![CDATA[MJ Bizarria]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Archondo]]></surname>
<given-names><![CDATA[ME del Llano]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[A Ribeiro da]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidade Santo Amaro  ]]></institution>
<addr-line><![CDATA[São Paulo ]]></addr-line>
<country>Brasil</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2020</year>
</pub-date>
<volume>30</volume>
<numero>1</numero>
<fpage>33</fpage>
<lpage>36</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1699-714X2020000100010&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1699-714X2020000100010&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1699-714X2020000100010&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO As infecções agudas do trato respiratório inferior (IATRIs) são a primeiras causas de mortes nos países de baixa renda e a quarta nos países de média renda, que incluem o Brasil. O vírus sincicial respiratório (VSR) é o principal agente de infecções agudas do trato respiratório inferior, a causa mais conhecida bronquiolite, entre lactentes e jovens crianças. O palivizumabe é um anticorpo monoclonal imunoglobulina G subclasse 1 (IgG1) humanizado indicado para infecções do trato respiratório causado pelo VSR. Desenvolvimento de protocolo de imunização, e monitoramento do uso do palivizumabe em pacientes pediátricos de alto risco; verificando se a profilaxia com o palivizumabe reduz as taxas de internações e de mortalidade por VSR. O farmacêutico é parte fundamental no desenvolvimento dos protocolos clínicos, pois realiza um importante trabalho no seguimento farmacoterapêutico. Estudo observacional, prospectivo, em crianças com o risco de infecção grave por VSR que receberam palivizumabe de acordo com os critérios clínicos estabelecidos no Protocolo Federal da Portaria nº 522 de 13/05/2013. Os indivíduos foram seguidos por meio de visitas mensais. Implantação do protocolo de uso do palivizumabe dentro da instituição de saúde, nele foram estabelecidos, parâmetros e padrões, visando uma maior agilidade e eficiência dos processos. Foram acompanhados 14 neonatos e jovens crianças, 42,8% foram prematuros, 28,5% apresentavam displasia broncopulmonar e 28,5% cardiopatia congênita. Três óbitos (21,4%) foram registrados durante o acompanhamento. Os resultados mostraram que a imunização passiva com o palivizumabe é uma ferramenta importante na prevenção de infecções pelo VSR.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY Acute lower respiratory tract infections (IATRIs) are the main cause of death in low-income countries and the fourth in middle-income countries, which include Brazil. Respiratory syncytial virus (RSV) is the main agent of acute lower respiratory tract infections, the most well known cause of bronchiolitis, among infants and young children. Palivizumab is a humanized immunoglobulin G subclass 1 (IgG1) monoclonal antibody indicated for respiratory tract infections caused by RSV. The pharmacist is a fundamental part in the development of clinical protocols, as it performs an important work in the pharmacotherapeutic follow-up. Development of an immunization protocol and monitoring the use of palivizumab in high-risk pediatric patients; verifying whether prophylaxis with palivizumab reduces hospitalization rates and RSV mortality. Observational prospective study in children at risk of severe RSV infection who received palivizumab according to the clinical criteria established in the Federal Protocol of Administrative Rule nº 522 of 05/13/2013. Children were followed through monthly visits. Implementation of the protocol for the use of palivizumab on the health institution, in which parameters, standards and parameters were established, aim at greater agility and efficiency of the processes. 14 neonates and young children were followed, 42.8% were premature, 28.5% had bronchopulmonary dysplasia and 28.5% had congenital heart disease. Three deaths (21.4%) were recorded during follow-up. The results showed that passive immunization with palivizumab are an important tool in the prevention of RSV infections.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Vírus sincicial respiratório (VSR)]]></kwd>
<kwd lng="pt"><![CDATA[palivizumabe]]></kwd>
<kwd lng="pt"><![CDATA[pediatria]]></kwd>
<kwd lng="en"><![CDATA[Respiratory syncytial virus (RSV)]]></kwd>
<kwd lng="en"><![CDATA[palivizumab]]></kwd>
<kwd lng="en"><![CDATA[pediatrics]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prato]]></surname>
<given-names><![CDATA[MIC]]></given-names>
</name>
<name>
<surname><![CDATA[Silveira]]></surname>
<given-names><![CDATA[A da]]></given-names>
</name>
<name>
<surname><![CDATA[Neves]]></surname>
<given-names><![CDATA[ET]]></given-names>
</name>
<name>
<surname><![CDATA[Bulboltz]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Doenças respiratórias na infância: uma revisão integrativa]]></article-title>
<source><![CDATA[Rev Soc Bras Enferm Ped]]></source>
<year>2014</year>
<volume>14</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>33</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferone]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Berezin]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Durigon]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
<name>
<surname><![CDATA[Finelli]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Felício]]></surname>
<given-names><![CDATA[MCC]]></given-names>
</name>
<name>
<surname><![CDATA[Storni]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical and epidemiological aspects related to the detection of adenovirus or respiratory syncytial virus in infants hospitalized for acute lower respiratory tract infection]]></article-title>
<source><![CDATA[J Pediatr (Rio J)]]></source>
<year>2014</year>
<volume>90</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>42-9</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="">
<source><![CDATA[Boletim da Sociedade Brasileira de Pediatria]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Monteiro]]></surname>
<given-names><![CDATA[AIMP]]></given-names>
</name>
<name>
<surname><![CDATA[Bellei]]></surname>
<given-names><![CDATA[NCJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sousa]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[AMN dos]]></given-names>
</name>
<name>
<surname><![CDATA[Weckx]]></surname>
<given-names><![CDATA[LY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Respiratory infections in children up to two years of age on prophylaxis with palivizumabe]]></article-title>
<source><![CDATA[Rev Paul Pediatr]]></source>
<year>2014</year>
<volume>32</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>152-8</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<collab>Brasil. Ministério da Saúde</collab>
<article-title xml:lang=""><![CDATA[Protocolo de uso do Palivizumabe]]></article-title>
<source><![CDATA[Diário Oficial da República Federativa do Brasil]]></source>
<year>2013</year>
<page-range>43</page-range><publisher-loc><![CDATA[Brasília, DF ]]></publisher-loc>
<publisher-name><![CDATA[Poder Executivo]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Toma]]></surname>
<given-names><![CDATA[TS]]></given-names>
</name>
<name>
<surname><![CDATA[Venancio]]></surname>
<given-names><![CDATA[SI]]></given-names>
</name>
<name>
<surname><![CDATA[Martins]]></surname>
<given-names><![CDATA[PN]]></given-names>
</name>
<name>
<surname><![CDATA[Sato]]></surname>
<given-names><![CDATA[HK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prophylactic use of palivizumab in the prevention of respiratory syncytial virus infection in high-risk children]]></article-title>
<source><![CDATA[Bol Inst Saúde (Impr.)]]></source>
<year>2013</year>
<volume>14</volume>
<numero>2</numero>
<issue>2</issue>
<publisher-loc><![CDATA[São Paulo ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="">
<collab>Brasil. Ministério da Saúde</collab>
<source><![CDATA[Estabelecer a sazonalidade do vírus sincicial respiratório no Brasil e oferecer esclarecimentos referentes ao protocolo de uso do palivizumabe]]></source>
<year>2012</year>
<publisher-loc><![CDATA[Brasília, DF ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Incognito]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Ulbrandt]]></surname>
<given-names><![CDATA[ND]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion]]></article-title>
<source><![CDATA[Journal of Virology]]></source>
<year>2010</year>
<volume>84</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>8132-40</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="book">
<source><![CDATA[Synagis® Palivizumabe. Farm. Resp.: Carlos E. A. Thomazini CRF-SP nº 24762]]></source>
<year></year>
<publisher-name><![CDATA[AbbVie Farmacêutica Ltda]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="">
<collab>Associação Médica Brasileira e Conselho Federal de Medicina</collab>
<source><![CDATA[Projeto Diretrizes. Aderência a Tratamento Medicamentoso]]></source>
<year>2009</year>
</nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[RZ]]></given-names>
</name>
<name>
<surname><![CDATA[Ziani]]></surname>
<given-names><![CDATA[PB]]></given-names>
</name>
</person-group>
<source><![CDATA[Atuação do Farmacêutico em Protocolos Clínicos: Gerencia de Relações Farmacêuticas]]></source>
<year>2010</year>
<numero>2</numero>
<issue>2</issue>
<publisher-name><![CDATA[Astra Zeneca do Brasil Ltda]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Cummins]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bayliss]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sandercock]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Burls]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation]]></article-title>
<source><![CDATA[Health Technology Assessment Group]]></source>
<year>2008</year>
</nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Checchia]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Nalysnyk]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fernandes]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
<name>
<surname><![CDATA[Mahadevia]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Fahrbach]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Welliver]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and metaanalysis]]></article-title>
<source><![CDATA[PediatrCrit Care Med]]></source>
<year>2011</year>
<volume>12</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>580-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<collab>IMpact-RSV Study Group</collab>
<article-title xml:lang=""><![CDATA[Palivizumab, a humanized respiratory syncytial virus monoclonalantibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants]]></article-title>
<source><![CDATA[Pediatric]]></source>
<year>1998</year>
<volume>102</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>531-7</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
